One of CCR’s greatest strengths is our unmatched broad integration of basic and clinical scientists, where basic laboratories adjoin clinical wards. Thanks to this tight collaboration of researchers across disciplines and settings, we are uniquely able to knit together insights from preclinical disease models with science-based approaches to human clinical treatment.
Our collaborative model allows us to identify new cancer therapies, both single agents and combinations, and bring them rapidly through early development and clinical testing and, if successful, partner with extramural collaborators to ensure that they are quickly brought to widespread trials and hopefully into clinical practice. Our structure also enables us to find novel ways to detect cancer early and even prevent it, largely through building powerful new imaging technologies that allow us to “see” cancer even in its initial stages.
All CCR clinical trials take place at the NIH Clinical Center located in Bethesda, Maryland, the world’s largest clinical research center. Our trials are open to patients, regardless of where they live in the United States
CCR's clinical-translational research program:
- Focuses on molecularly-guided patient care
- Integrates advanced biomedical technologies into every clinical trial
- Provides the infrastructure that enables bench-to-bedside-to-bench efforts
- Is committed to studying rare cancers and treating underserved patient populations
- Invests in new transformational technologies in genomics and imaging
- Is supported by the expertise and resources of the NIH Clinical Center